SALT LAKE CITY — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that on March 9, 2026, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price rule. As a result, the previously disclosed listing matter has been closed and the Company’s shares will resume trading on Nasdaq effective March 11, 2026.
Co-Dx believes that regaining Nasdaq compliance enhances the Company’s capital markets flexibility and provides confidence to shareholders, while the Company continues to focus on completing clinical performance studies and regulatory clearance pathways that will allow the Company to bring the Co-Dx PCR point-of-care diagnostics platform* to market.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) to identify genetic markers for use in applications other than infectious disease.